Over recent years, hip resurfacing has been performed in young, active patients, including women in their child bearing years. Current work investigating the transplacental passage of metal ions (cobalt and chromium) suggests significant passage of ions across the placenta in mothers with metal on metal hip resurfacing. In vitro studies show that cobalt and chromium can create DNA and chromosome damage in human cells. The consequences of this ion transfer on the child during fetal development and thereafter have not been fully quantified. We report on 3 patients with metal on metal hip resurfacings who had the prosthesis in situ during pregnancy. Our data show that umbilical cord blood chromium levels are under a quarter of the maternal serum levels. Cord blood cobalt levels are approximately half that of maternal blood. All 3 children are healthy. Although there was transplacental passage of ions, there was no significant effect on the child in these cases. We did not show any teratogenic effect of metal ions on the child, and this is consistent with the reported literature.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5301/HIP.2012.9100 | DOI Listing |
Toxicon
December 2024
Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, S.P., Brazil; Institute of Environmental, Chemical and Pharmaceutical Sciences, Federal University of São Paulo (ICAQF-UNIFESP), Diadema, S.P., Brazil. Electronic address:
L-Mimosine is the main active component of the plant Leucaena leucocephala. Due to its metal-chelating mechanism, it interacts with various metabolic pathways in living organisms, making it a potential pharmacological target, although it also leads to toxicity. The present study aimed to investigate the transplacental passage of L-mimosine and its effects on embryofetal development.
View Article and Find Full Text PDFObstet Gynecol
January 2025
Division of Pulmonary and Critical Care Medicine, the Division of Pediatric Pulmonology, and the Division of Maternal Fetal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Life (Basel)
November 2024
Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Gestational pemphigoid is a rare, autoimmune, subepidermal bullous disease with an incidence of 1 in 50,000 pregnancies, displaying itself through pruritic erythema and urticarial papules and plaques that evolve into tense bullae. Histopathological findings consist of subepidermal vesicles with perivascular eosinophils and lymphocytes, and direct immunofluorescence reveals C3 complement and, more rarely, IgG in a linear band along the basement membrane. The course is usually self-limiting within 6 months after delivery but, later, can be triggered by subsequent pregnancies, menstruation, or treatment with oral contraceptives.
View Article and Find Full Text PDFNeoreviews
November 2024
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Evanston Hospital - Endeavor Health, University of Chicago Pritzker School of Medicine, Evanston, IL.
Drug Deliv Transl Res
October 2024
Department of Obstetrics, Wilhemina Children's Hospital, UMC Utrecht, Utrecht, The Netherlands.
Medication use during pregnancy poses risks to both the mother and the fetus. These risks include an elevated potential for fetotoxicity due to placental drug transport. Nanomedicines offer a promising solution by potentially preventing trans-placental passage.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!